Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related ParametersFebruary 22nd 2022
Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.
Examining Racial Genomics in Prostate CancerAugust 8th 2020
Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
ctDNA Identifies Adjuvant MRD Positivity, Relapse in Lung CancerMay 2nd 2020
Results from the Lung TRACERx study, in which the biomarker was found, has the potential to set the stage for future clinical trials that are structured to increase the standard-of-care dosage in patients with non–small cell lung cancer (NSCLC) who become MRD-positive after surgery.